AN award-winning Hartlepool company is going national in a campaign which could save the NHS millions of pounds.
Hart Biologicals, the current Hartlepool Business of the Year, is teaming up with a PR company Onyx Health to demonstrate to healthcare providers the cost saving advantages of its anti-coagulation monitoring systems.
The Queens Meadow Business Park-based firm produces the Thrombi-Stat INR testing system which is used to monitor how quickly a patient’s blood clots.
Company bosses say it has the potential to save the NHS £40m if used nationally.
It is estimated that 800,000 patients take a product called Warfarin each year to stop their blood forming clots which can lead to a stroke or heart attack.
Each patient has to be carefully monitored throughout the year to check that their blood has not got too thin or too sticky that it forms a clot. This continual testing is a major expense to the NHS.
Hart Biologicals managing director Alby Pattison said the time was right to “demonstrate to the NHS the real cost savings that could be made with our testing systems.”
Because of that, he said, the company decided to appoint Onyx Health to work on the programme with Hart Biologicals to support it both in the UK and also globally.
The campaign devised by Onyx Health will target the financial decision makers in hospitals and primary care, showing them the cost advantages of using the Thrombi-Stat INR testing system.
The programme will also focus on organisations submitting tenders for community based anti-coagulation testing.
Onyx Health is the brainchild of Karen Winterhalter who said: “We are delighted that Hart Biologicals chose to work with us and hope this is only one of many successful campaigns we can undertake for healthcare businesses in the North East.”